Immunotherapy in Localized Colorectal Cancer: Current Practice and Future Directions
- 1 June 2026
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in American Society of Clinical Oncology Educational Book
- Vol. 46 (3) , e520600
Abstract
Immune checkpoint inhibitors (ICIs) have fundamentally transformed the treatment landscape for localized colorectal cancer (CRC), particularly for the mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) subgroups. This review evaluates the current clinical evidence and evolving paradigms of immunotherapy in early-stage CRC. In localized MSI-H colon and rectal cancers, neoadjuvant immunotherapy has demonstrated unprecedented efficacy, yielding near-universal major pathologic responses and high rates of pathologic complete responses. For MSI-H rectal cancer, these deep and sustained clinical complete responses have established nonoperative management as a viable, organ-preserving standard of care for highly selected patients undergoing rigorous multidisciplinary surveillance. Despite these rapid advancements, critical questions remain regarding optimal regimen selection, treatment duration, and the integration of circulating tumor DNA (ctDNA) for molecular residual disease monitoring. Although ctDNA is a promising dynamic biomarker, it currently cannot replace definitive pathologic assessment outside of clinical trials. Furthermore, extending the benefits of immunotherapy to the majority of patients with microsatellite-stable (MSS) CRC represents a significant unmet clinical need. Current evidence for ICIs in localized MSS disease remains limited, although investigational combination strategies incorporating radiation, chemotherapy, and novel immune modulators are yielding hypothesis-generating signals. Future progress hinges on precision de-escalation protocols and biomarker-driven, response-adapted trial designs to validate surrogate end points and optimize patient outcomes across all localized CRC subtypes.Keywords
This publication has 74 references indexed in Scilit:
- 74MO mFOLFOX6 + bevacizumab + PD-1 monoclonal antibody in locally advanced MSS CRC (BASKETⅡ): A prospective, single-arm, open-label, phase II studyAnnals of Oncology, 2024
- Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 studyAnnals of Oncology, 2024
- Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trialAnnals of Oncology, 2024
- Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trialAnnals of Oncology, 2024
- 243P Neoadjuvant XELOX chemotherapy with or without cadonilimab in locally advanced pMMR rectal cancer: Preliminary results from a randomized, open-label phase II trialAnnals of Oncology, 2024
- Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapyCancer Cell, 2023
- P-172 VOLTAGE cohort D: Preoperative chemoradiotherapy followed by consolidation nivolumab plus ipilimumab in patients with locally advanced rectal cancerAnnals of Oncology, 2023
- Use of Total Neoadjuvant Therapy for Locally Advanced Rectal CancerJAMA Oncology, 2021
- 491P Neoadjuvant nivolumab in early stage colorectal cancerAnnals of Oncology, 2020
- Role of Local Radiation Therapy in Cancer ImmunotherapyJAMA Oncology, 2015